Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis.

Kelly J NorsworthyFlora MulkeyEmma C ScottAshley F WardDonna PrzepiorkaRosane CharlabSarah E DorffAlbert DeisserothDickran KazandjianRajeshwari SridharaJulia A BeaverAnn T FarrellR Angelo de ClaroRichard Pazdur

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)

DS is a common and potentially fatal adverse reaction of IDH inhibitors, and use of standardized diagnostic criteria may aid in earlier diagnosis and treatment.See related commentary by Zeidner, p. 4174.

Keyphrases

drug administration
acute myeloid leukemia
wild type
low grade
acute lymphoblastic leukemia
diffuse large b cell lymphoma
multiple myeloma
allogeneic hematopoietic stem cell transplantation
risk assessment
high grade
human health
climate change
drug induced
electronic health record
smoking cessation